Deaths / year
0
GBD (indicative unless refreshed)
DALYs / year
3,000,000
GBD
Pathogen
Mite
Post-infectious
Lasting sequela
Persistent symptoms
n/a
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Secondary bacterial infection -> post-streptococcal (acute rheumatic fever, glomerulonephritis)
Classification
Lasting sequela
Onset
downstream
Persistent-symptom %
not quantified as a single figure (see notes)
Source: Romani 2015 Lancet ID
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Household/contact treatment | Prevention | Approved | Simultaneous treatment of contacts | WHO EML / standard of care |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Permethrin 5% cream | Topical scabicide | Approved | First-line topical treatment | WHO EML / standard of care |
| Ivermectin (oral) | Anthelmintic | Approved | Mass drug administration and crusted scabies | WHO EML / standard of care |
| Benzyl benzoate 25% | Topical scabicide | Approved | Alternative topical | WHO EML / standard of care |
| CHLORHEXIDINE GLUCONATEPipeline | Small molecule | Phase 2 | — | Open Targets (clinical pipeline) |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Secondary bacterial infection treatment | Antibiotic | Approved | Post-streptococcal sequelae prevention | Romani 2015 Lancet ID |
Associated drug targets (Open Targets): FLG, FTO, NR3C1, LY6D, PRSS53, SLC39A8
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0021201 · Updated 2026-07-10. Associations, not a diagnostic test.